ClinicalTrials.gg
TerminatedNCT07030907Updated Nov 9, 2026

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

A Phase 1 interventional study of OPB-101 in Ovarian Cancer Recurrent, Ovarian Cancer and Platinum Resistant Ovarian Cancer, sponsored by Outpace Bio, Inc.. Terminated at 4 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Outpace Bio, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Business decision
Updated Oct 26, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,780 studies in Ovarian Neoplasms with a site in United States — 276 open to participants now, 452 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Enrollment
1,408th of 1,499
3 · median 47
Started
2025
with 76 others
Phase 1
548 of 1,780
73 open now
Registered
1,692nd of 1,780
by date

Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 1,408th largest by enrollment of the 1,499 interventional ones that give a count, is one of 77 that started in 2025, is one of 548 in phase 1, and was the 1,692nd registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

276 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

271 more — sign in →

All 276 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,780 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101.

Participants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time treatment. Participants will be in the hospital when they receive OPB-101 and then be checked at the clinical site frequently for the first few months.

Read the detailed description

A phase 1a/b study to evaluate the safety and efficacy of OPB-101, an autologous mesothelin (MSLN) CAR T cell therapy with antigen-dependent expression of OUTSMART™ designed IL-2 cytokine in platinum-resistant ovarian cancer.

03

Conditions studied

  • Ovarian Cancer Recurrent
  • Ovarian Cancer
  • Platinum Resistant Ovarian Cancer

Browse trials for

Keywords

  • Outpace
  • Ovarian cancer
  • Advanced ovarian cancer
  • cell therapy
  • CAR T
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years of age at the time of signing the form.
  2. confirmed diagnosis of high grade serous epithelial ovarian, peritoneal, or fallopian tube cancer based on local histopathological findings.
  3. Recurrent platinum-resistant disease defined as: Disease that has recurred within 6 months of the last receipt of platinum-based therapy.
  4. Received at least 2 including a platinum-based chemotherapy.
  5. Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1/2 mutation.
  6. .
  7. Consent to provide archived tumor tissue sample.
  8. performance status of 0 or 1.
  9. Adequate organ function.
  10. Alkaline phosphatase ≤ 2.5 x
  11. ≤ Grade 1 dyspnea and oxygen saturation levels (SpO2) > 92% on room air.
  12. ≥ 50%
  13. of ≥ 3 months
  14. Adequate venous access.
  15. Negative screen for infectious disease markers.
  16. Negative serum pregnancy test.
  17. Abstain from heterosexual activity or to use 2 forms of effective methods of .

Note: Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  1. Women of who are pregnant or breastfeeding.
  2. Uncontrolled bacterial, fungal, or viral infections.
  3. Active infection requiring systemic therapy.
  4. Bleeding or thrombotic disorders or at risk for severe hemorrhage.
  5. Any form of primary immunodeficiency.
  6. Had an allogenic tissue/solid organ transplant.
  7. Active disease.
  8. Concurrent treatment with systemic high dose .
  9. Unresolved acute effects of any prior therapy.
  10. Active invasive cancer other than the cancer under study.
  11. Significant lung disease.
  12. pericardial effusion.
  13. Prior radiotherapy within 2 weeks of start of study intervention.
  14. No major surgery within 28 days prior to enrollment.
  15. Received agents or tumor vaccines.
  16. Received chemotherapy within the previous 3 weeks.
  17. History of grade ≥ 3 ascites.
  18. Active CNS involvement.
  19. Received a within 30 days prior to study treatment.
  20. Received prior CAR T cell therapy.
  21. Received prior mesothelin targeted therapy.
  22. Dependent on intravenous hydration or total parenteral nutrition. Note: Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    OPB-101 Treatment Arm

    Biological: OPB-101

Interventions

  • BiologicalOPB-101

    An autologous mesothelin (MSLN) CAR T cell therapy with antigen-dependent expression of OUTSMART designed IL-2 cytokine

06

What researchers measure

Primary outcomes

  1. Safety

    Incidence of dose-limiting toxicities (DLTs)

    Time frame: 28 days

  2. Safety

    Incidence of all treatment-emergent adverse events (TEAEs); Grade 3, 4, 5 TEAEs, serious adverse events (SAEs); deaths due to TEAEs and all deaths

    Time frame: 2 years

  3. Safety

    To determine the maximum tolerated dose (MTD) of OPB-101 and/or recommended Phase 1b dose(s)

    Time frame: 2 years

07

Study locations

4 sites
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Roswell Park
    Buffalo, New York 14203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2025 to primary completion in Sep 2026, 15 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion May 2028 → Sep 2026 and completion May 2030 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2025
First posted
Jun 22, 2025
StartActual
Jun 16, 2025
Primary completionActual
Sep 30, 2026was May 2028
CompletionActual
Oct 15, 2026was May 2030
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Business decision
changed Oct 26, 2026
Primary completion
May 15, 2028→Sep 30, 2026 (actual)
Oct 26, 2026
Study completion
May 15, 2030→Oct 15, 2026 (actual)
Oct 26, 2026
Enrollment
30 (estimated)→3 (actual)
Oct 26, 2026
Show all 2 updates
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 26, 2026
    Recruiting→Terminated
    Why stopped Business decision
    Primary completion May 15, 2028→Sep 30, 2026 (now actual)
    Study completion May 15, 2030→Oct 15, 2026 (now actual)
    Enrollment 30 (estimated)→3 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07030907
Lead sponsor
Outpace Bio, Inc.
Responsible party
Sponsor
First posted
Jun 22, 2025
Start date
Jun 16, 2025
Primary completion
Sep 30, 2026
Completion
Oct 15, 2026
Last update
Nov 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion